Immunome, Inc. IMNM
General analysis — not personal advice.
ASCO is now in the price and the market reaction has been negative on elevated volume, increasing the risk of continued volatility and weak technicals.
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Market sentiment
Sentiment has deteriorated materially as the stock broke to 52-week lows after ASCO, suggesting the market either “sold the news” or is reassessing probability/timing of regulatory outcomes and commercial potential despite supportive analyst commentary.
Why this signal
ASCO is now in the price and the market reaction has been negative on elevated volume, increasing the risk of continued volatility and weak technicals. However, the core upside remains tied to regulatory milestones (FDA filing acceptance/review timeline and later decision), so the appropriate stance remains to review/resize exposure rather than aggressively averaging down or adding ahead of clearer signals.
Maintain a core position if already owned, but avoid aggressive adds ahead of FDA acceptance/ASCO; consider scaling exposure around catalysts based on risk budget.
Recent News
On August 11, 2026, Immunome reported its second quarter 2026 financial results and confirmed $520.0 million in total cash, cash equivalents, and marketable securities. The U.S. FDA accepted the company's New Drug Application for lead asset varegacestat with a target PDUFA action date of April 28, 2027. Immunome also advanced its clinical pipeline by dosing the first patients in Phase 1 trials for candidates IM-1617 and IM-3050.
Catalysts
FDA: NDA acceptance (varegacestat)
Dilution Risk
Assessment: Low
What Firelda Watch includes for Immunome, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more